Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeUp to 60
SponsorSt. Jude Children's Research Hospital

About this trial

The purpose of this study is to test whether giving treatment before surgery helps babies who are newly diagnosed with Infant-Type Hemispheric Glioma (IHG) have safer and better surgery results.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient with presumptive or suspected (new) diagnosis of Infant-Type Hemispheric Glioma (IHG)

Patient age at diagnosis is from birth to ≤ 60 months

Patient has MRI/CT scan imaging of a supra-tentorial, hemispheric tumor avail-able for review before screening consent.

Patient is willing to undergo a biopsy procedure to confirm tissue diagnosis.

Disqualifiers

Age > 60 months

Any prior cancer-directed therapy

Organ Dysfunction, or a medical condition that, in the principal investigator's judgment, could compromise their ability to tolerate or absorb protocol therapy or would interfere with study procedures and results.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Alectinib

    Drug

    By mouth, nasogastric, or gastronomy/stomach tube, Day 1-28

  • Entrectinib

    Drug

    By mouth, nasogastric, or gastronomy/stomach tube, Day 1-28

  • Surgery

    Procedure/Surgery

    Primary surgery (Strata A, B, and C) post Neoadjuvant therapy with a goal of attaining gross total (GTR) or near total resection (NTR) of the tumor.

  • Cyclophosphamide

    Drug

    IV (intravenous) day 1

  • Etoposide

    Drug

    IV (intravenous) days 1 and 2

  • Carboplatin

    Drug

    IV (intravenous) day 2

  • Filgrastim

    Biological/Vaccine

    Subcutaneous (under the skin) or IV (intravenous) day 3

  • Pegfilgrastim

    Biological/Vaccine

    Subcutaneous (under the skin) day 3

  • Surgery

    Procedure/Surgery

    Primary surgery (Strata A, B, and C) post Neoadjuvant therapy with a goal of attaining gross total (GTR) or near total resection (NTR) of the tumor.

Treatment groups

50 Participants
are divided into 4 treatment groups
Group A: Stratum AExperimental treatment 7 interventions
Group B: Stratum BExperimental treatment 7 interventions
Group C: Stratum CExperimental treatment 5 interventions
Group D: Stratum DExperimental treatment 5 interventions

Trial outcomes

Primary outcomes

1

Rate of Complete Tumor Response (CTR) among patients in Strata A, B, and C

The proportion of patients whose extent of tumor resection meets criteria for gross total / near total resection (GTR/NTR) after neoadjuvant therapy and surgery.

Time frame
approximately 4 months after enrollment
2

Rate of safe surgical resection among patients in Strata A, B, and C

Proportion of patients whose surgery is completed without clinically significant intra-operative blood loss/hemorrhage. Success for this outcome measure will include surgery without any of the following: (i) Initiation of massive transfusion protocol- i.e., requiring more than one volume (80ml/Kg) of transfusion over a period of 24 hours (ii) Hemorrhage leading to cessation of surgery (iii) Hemorrhagic complications leading to second neurosurgery within 72 hours of the first surgery.

Time frame
Up to 72 hours after surgery

Secondary outcomes

1

Event free survival (EFS)

EFS is defined as time from enrollment for treatment (including bridge therapy) until progression, subsequent malignancy or death for any reason or until last follow-up, whichever is earlier.

Time frame
2 years
2

Overall survival (OS)

OS is defined as time from enrollment for treatment (including bridge therapy) until death for any reason or until last follow-up, whichever is earlier.

Time frame
2 years
3

Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: BSID-4

Time frame
Pre-surgery/baseline and after the intervention/procedure/primary surgery for up to 12 weeks
4

Change in neurodevelopment and cognitive performance pre- and post-primary surgery in infants with newly diagnosed IHG treated with molecularly directed neoadjuvant treatment: NIH Baby Toolbox

Time frame
Pre-surgery/baseline and after the intervention/procedure/primary surgery for up to 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

St. Jude Children's Research Hospital

Lead sponsor

St. Baldrick's Foundation

Collaborator

Genentech, Inc.

Collaborator

This trial is not recruiting at the moment. You can still explore other options: